<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nephrol Dial Transplant</journal-id><journal-id journal-id-type="publisher-id">ndt</journal-id><journal-id journal-id-type="hwp">ndt</journal-id><journal-title-group><journal-title>Nephrology Dialysis Transplantation</journal-title></journal-title-group><issn pub-type="ppub">0931-0509</issn><issn pub-type="epub">1460-2385</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20921291</article-id><article-id pub-id-type="pmc">3084439</article-id><article-id pub-id-type="doi">10.1093/ndt/gfq598</article-id><article-id pub-id-type="publisher-id">gfq598</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol</article-title><alt-title alt-title-type="right-running">Calcitriol pharmacokinetics: effect of P binders</alt-title><alt-title alt-title-type="left-running">D. Pierce <italic>et al.</italic></alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pierce</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hossack</surname><given-names>Stuart</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Poole</surname><given-names>Lynne</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>Antoine</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Van Heusen</surname><given-names>Heather</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Smyth</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Shire Pharmaceutical Development Ltd</institution>, <addr-line>Chineham, Hampshire</addr-line>, <country>UK</country></aff><aff id="aff2"><label>2</label><institution>Covance Clinical Research Unit Ltd</institution>, <addr-line>Leeds</addr-line>, <country>UK</country></aff><aff id="aff3"><label>3</label><institution>Shire Pharmaceuticals</institution>, <addr-line>Wayne, PA</addr-line>, <country>USA</country></aff></contrib-group><author-notes><corresp><italic>Correspondence and offprint requests to</italic>: David Pierce; E-mail: 
<email>DPierce@shire.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>4</day><month>10</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>10</month><year>2010</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>26</volume><issue>5</issue><fpage>1615</fpage><lpage>1621</lpage><history><date date-type="received"><day>26</day><month>4</month><year>2010</year></date><date date-type="rev-recd"><day>10</day><month>8</month><year>2010</year></date><date date-type="accepted"><day>6</day><month>9</month><year>2010</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Oxford University Press</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.5"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.5">http://creativecommons.org/licenses/by-nc/2.5</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><bold>Background.</bold> Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD). Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol.</p><p><bold>Methods.</bold> This was a three-period, crossover study in healthy volunteers. Forty-one individuals were randomized to one of six possible sequences, each consisting of three treatment periods separated by washouts. The treatments were calcitriol (1&#x000a0;&#x003bc;g at lunch), calcitriol with lanthanum carbonate (3000&#x000a0;mg/day) and calcitriol with sevelamer carbonate (7200&#x000a0;mg/day). Serum calcitriol levels were assessed at baseline and throughout the study.</p><p><bold>Results.</bold> Co-administration of lanthanum carbonate with calcitriol had no significant effect on area under the curve over 48&#x000a0;h (AUC<sub>0&#x02013;48</sub>) for serum exogenous calcitriol [least-squares (LS) mean, calcitriol with lanthanum carbonate vs calcitriol alone: 429&#x000a0;pg h/mL vs 318&#x000a0;pg h/mL, respectively; P = 0.171]. Similarly, there was no significant effect on maximum concentration (<italic>C</italic><sub>max</sub>). In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC<sub>0&#x02013;48</sub>: 137&#x000a0;pg h/mL vs 318&#x000a0;pg h/mL, respectively; P = 0.024; LS mean <italic>C</italic><sub>max</sub>: 40.1&#x000a0;pg/mL vs 49.7&#x000a0;pg/mL, respectively; P &#x0003c; 0.001).</p><p><bold>Conclusions.</bold> Sevelamer carbonate significantly reduces serum concentrations of exogenous calcitriol when administered concomitantly with oral calcitriol, whereas lanthanum carbonate has no significant effect. This should be considered when treating CKD patients who require phosphate binders and oral vitamin D.</p></abstract><kwd-group><title>Keywords</title><kwd>bioavailability</kwd><kwd>calcitriol</kwd><kwd>chronic kidney disease</kwd><kwd>lanthanum carbonate</kwd><kwd>sevelamer carbonate</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Vitamin D insufficiency and deficiency are common in patients with chronic kidney disease (CKD), owing to decreased synthesis of 1,25-dihydroxyvitamin D (calcitriol, the active form of vitamin D) in the kidney [<xref rid="ref1 ref2" ref-type="bibr">1,2</xref>]. A decrease in 1,25-dihydroxyvitamin D, along with an increase in parathyroid hormone, is one of the earliest changes seen in mineral metabolism parameters in patients with CKD and this decrease tends to worsen as CKD progresses [<xref rid="ref3" ref-type="bibr">3</xref>]. Vitamin D insufficiency is strongly associated with hyperparathyroidism [<xref rid="ref4" ref-type="bibr">4</xref>], as well as an increased risk of cardiovascular events and changes in bone metabolism [<xref rid="ref5 ref6" ref-type="bibr">5,6</xref>]. The Kidney Disease Outcomes Quality Initiative and the Kidney Disease: Improving Global Outcomes guidelines both recommend that vitamin D insufficiency and deficiency are treated appropriately [<xref rid="ref7 ref8" ref-type="bibr">7,8</xref>]. Several preparations of vitamin D and vitamin D analogues are available; some are administered orally and others intravenously. Such agents have been found to be extremely effective in controlling hyperparathyroidism in patients with advanced kidney disease [<xref rid="ref9" ref-type="bibr">9</xref>] and in reducing mortality in patients on haemodialysis [<xref rid="ref10" ref-type="bibr">10</xref>]. Thus, it is important for nephrologists to be aware of any drug&#x02013;drug interactions that may impact on the effectiveness of vitamin D treatments.</p><p>Phosphate binders are often used to sequester dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and helping to manage hyperphosphataemia in patients with CKD. Several binders are currently available; among these, non-calcium-based lanthanum carbonate (FOSRENOL<sup>&#x000ae;</sup>, Shire Pharmaceuticals, Basingstoke, UK) and sevelamer (Renagel<sup>&#x000ae;</sup> and Renvela<sup>&#x000ae;</sup>, Genzyme Corporation, Cambridge, MA, USA) have been shown to be effective in reducing serum phosphorus levels in patients with CKD on dialysis [<xref rid="ref11 ref12" ref-type="bibr">11,12</xref>] and may improve survival, in comparison with calcium-based binders, in patients over 65&#x000a0;years of age [<xref rid="ref13 ref14" ref-type="bibr">13,14</xref>]. These non-calcium-based binders have been developed as an alternative to the older calcium-based agents, which may increase the progression of calcification [<xref rid="ref15" ref-type="bibr">15</xref>].</p><p>The mechanism of action of all phosphate binders involves direct physical binding of phosphate in the contents of the gastrointestinal tract. In addition to binding phosphate, sevelamer has a high affinity for bile salts [<xref rid="ref16" ref-type="bibr">16</xref>]. Indeed, it has been shown <italic>in vitro</italic> that bile salts displace phosphate from sevelamer, but not from lanthanum [<xref rid="ref17" ref-type="bibr">17</xref>]. As sevelamer binds bile salts, it may impair the absorption of fat-soluble molecules, such as vitamin D [<xref rid="ref18" ref-type="bibr">18</xref>]. Sevelamer hydrochloride has been shown to reduce the bioavailability of calcitriol in beagle dogs [<xref rid="ref19" ref-type="bibr">19</xref>], but no specific calcitriol interaction studies have been reported in humans. Sevelamer carbonate is a new formulation of sevelamer, which may also reduce the absorption of fat-soluble vitamins.</p><p>To date, there are no published clinical data in humans regarding the effect of sevelamer carbonate/hydrochloride or lanthanum carbonate on the absorption of the vitamin D supplement, oral calcitriol, which is indicated for patients with CKD who are vitamin D deficient. In this clinical pharmacology study, the effects of lanthanum carbonate and sevelamer carbonate on the pharmacokinetics of oral calcitriol in healthy volunteers were compared.</p></sec><sec sec-type="materials|methods" id="sec2"><title>Materials and methods</title><sec id="sec3"><title>Design</title><p>This was an open-label, three-period crossover study comparing the bioavailability of calcitriol (ROCALTROL<sup>&#x000ae;</sup>, Validus Pharmaceuticals, Inc. Parsippany, NJ, USA) during the following regimens:
<list list-type="bullet"><list-item><p>calcitriol alone (1&#x000a0;&#x003bc;g at lunch, given as two 0.5&#x000a0;&#x003bc;g capsules)</p></list-item><list-item><p>calcitriol (1&#x000a0;&#x003bc;g at lunch) with lanthanum carbonate (one 1000&#x000a0;mg tablet at breakfast, lunch and dinner)</p></list-item><list-item><p>calcitriol (1&#x000a0;&#x003bc;g at lunch) with sevelamer carbonate (2400&#x000a0;mg at breakfast, lunch and dinner, given as three 800&#x000a0;mg tablets).</p></list-item></list></p><p>The dose per day of lanthanum carbonate (3000&#x000a0;mg) was chosen based on the highest doses usually required in clinical studies; most patients received 1500&#x02013;3000&#x000a0;mg/day in order to reach targets [<xref rid="ref12 ref20 ref21" ref-type="bibr">12,20,21</xref>]. Data on the required dosage of sevelamer carbonate are limited; Ketteler <italic>et al.</italic> reported a final mean dose of 7800&#x000a0;mg/day in a recent treat-to-target study [<xref rid="ref22" ref-type="bibr">22</xref>]. Data on sevelamer hydrochloride suggest a mean dose requirement of 5400&#x02013;6900&#x000a0;mg/day [<xref rid="ref13 ref23 ref24 ref25 ref26" ref-type="bibr">13,23&#x02013;26</xref>] to achieve control of serum phosphate. Thus, we considered a daily dose of sevelamer carbonate of 7200&#x000a0;mg/day to represent a dose within the typical range used in clinical practice.</p><p>Eligible healthy volunteers were admitted to a single study centre and randomized to one of six treatment sequences (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>), with each sequence including all three treatment regimens. Treatment periods each lasted 3&#x000a0;days and were separated from each other by a 7-day washout. Study treatment was given only on day 1 of each treatment period. Identical meals were served across the treatment periods and contained 300&#x02013;400&#x000a0;mg of phosphorus and 200&#x02013;300&#x000a0;mg of calcium. Treatments were administered orally with 240&#x000a0;mL of de-ionized water half-way through ingestion of the meal. The study was undertaken in accordance with the Declaration of Helsinki, and all participants provided written informed consent.</p><fig id="fig1" position="float"><label>Fig.&#x000a0;1</label><caption><p>Study design. Study medications were administered orally with 240&#x000a0;mL of de-ionized water half-way through ingestion of the meal.</p></caption><graphic xlink:href="gfq598fig1"/></fig></sec><sec id="sec4"><title>Participants</title><p>Eligible healthy volunteers were aged 19&#x02013;45&#x000a0;years and had a body mass index of 20.0&#x02013;29.9&#x000a0;kg/m<sup>2</sup>. Women of childbearing potential and sexually active men were required to use an acceptable method of contraception. Exclusion criteria included current or recurrent disease that could affect the action, absorption or disposition of the investigational products; current or relevant previous history of any medical disorder that might require treatment or make the subject unlikely to be able to complete the study; significant illness within 2&#x000a0;weeks of the first dose of study medication; use of any medication within 2&#x000a0;weeks of the first study dose, with the exception of hormonal replacement therapy or hormonal contraceptives; a positive test for human immunodeficiency virus antibodies, hepatitis B surface antigens or hepatitis C antibodies; pregnancy or lactation; smoking or use of nicotine-containing products; a history of alcohol abuse, or consumption of more than 21&#x000a0;units/week for men or more than 14&#x000a0;units/week for women; routine consumption of more than 2&#x000a0;units of caffeine per day; inability to follow a standardized diet and meal schedule or inability to fast as required during the study; substantial changes in eating habits in the 30&#x000a0;days before first study dose; and use of any other investigational agents in the 30&#x000a0;days before first study dose.</p></sec><sec id="sec5"><title>Objectives and assessments</title><p>The primary objective was to assess the effects of lanthanum carbonate (1000&#x000a0;mg t.i.d. with meals) and sevelamer carbonate (2400&#x000a0;mg t.i.d. with meals) on the pharmacokinetics of oral calcitriol (1&#x000a0;&#x003bc;g o.d.). The primary endpoint was predefined as the change from baseline in area under the curve over 48&#x000a0;h (AUC<sub>0&#x02013;48</sub>) for exogenous calcitriol (i.e. day 1 total calcitriol minus baseline endogenous calcitriol). Secondary pharmacokinetic endpoints included maximum concentration (<italic>C</italic><sub>max</sub>), AUC until last measurable time point (AUC<sub>0&#x02013;<italic>t</italic></sub>) and time to maximum concentration (<italic>t</italic><sub>max</sub>) for exogenous calcitriol and all the above parameters for total calcitriol.</p><p>Blood samples for assessment of serum calcitriol levels were collected from each participant prior to lunch on the 2&#x000a0;days before study dosing in each treatment period (days &#x02212;&#x02009;2 and &#x02212;&#x02009;1) and at the following time points after dosing in each treatment period: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48&#x000a0;h. Serum concentrations of calcitriol were determined by a validated radioimmunoassay with a working range of 5&#x02013;210&#x000a0;pg/mL. Samples from the same individual for different treatment regimens were analysed in separate batches; however, an incurred sample reproducibility test confirmed acceptable inter-batch reproducibility. Serum calcitriol levels in quality control samples (12.5, 50.0 and 175&#x000a0;pg/mL) analysed alongside study samples were determined with an accuracy of between &#x02212;&#x02009;6.5 and 6.9% and a precision (inter-assay coefficient of variation) of between 7.3 and 9.5%. Baseline endogenous serum calcitriol levels were determined from the mean of values for days &#x02212;&#x02009;2 and &#x02212;&#x02009;1. Exogenous serum calcitriol values at each sampling time following dosing were calculated from the total serum concentration at that time minus the baseline endogenous serum calcitriol concentration. This method of determining exogenous calcitriol concentration could result in negative calculated values. Serum exogenous calcitriol AUC<sub>0&#x02013;48</sub> and AUC<sub>0&#x02013;<italic>t</italic></sub> were calculated using individual values for exogenous serum calcitriol levels and could also have negative values. AUC<sub>0&#x02013;48</sub>, AUC<sub>0&#x02013;<italic>t</italic></sub>, <italic>C</italic><sub>max</sub> and <italic>t</italic><sub>max</sub> for total calcitriol were also determined for each treatment.</p><p>The secondary objective was to evaluate the safety and tolerability of lanthanum carbonate and sevelamer carbonate when co-administered with calcitriol. This was assessed through recording of adverse events and laboratory assessments.</p></sec><sec id="sec6"><title>Statistical methods</title><p>Based on published data, the mean AUC for exogenous serum calcitriol corresponding to a dose of 1&#x000a0;&#x003bc;g oral calcitriol per day was estimated to be 256&#x000a0;pg h/mL [<xref rid="ref27" ref-type="bibr">27</xref>]. In this study, an inter-participant coefficient of variation of 22% was reported for total calcitriol levels (endogenous plus exogenous). Based on this degree of variability, it was estimated that a total of 30 participants would allow detection of a 20% reduction in AUC for serum calcitriol between calcitriol alone and calcitriol with lanthanum carbonate or sevelamer carbonate, with a two-sided significance level and 90% power. Assuming that the intra-participant coefficient of variation (which was not available) would be lower than the inter-participant variability, sample size was likely to have been overestimated.</p><p>The primary hypothesis tested was that there were no differences in the AUC<sub>0&#x02013;48</sub> for exogenous calcitriol when calcitriol was co-administered with either lanthanum carbonate (lanthanum carbonate + calcitriol versus calcitriol alone) or sevelamer carbonate (sevelamer carbonate + calcitriol versus calcitriol alone). The primary analysis was performed on the pharmacokinetic population, which consisted of all participants with no major deviations related to study drug intake for whom the primary pharmacokinetic data were considered sufficient and interpretable. AUC<sub>0&#x02013;48</sub>, AUC<sub>0&#x02013;<italic>t</italic></sub> and <italic>C</italic><sub>max</sub> for exogenous calcitriol were analysed using a mixed-effect linear model containing sequence group, period and treatment group as fixed effects and participant-within-sequence as the random effect. Baseline endogenous calcitriol was included as a covariate. AUC<sub>0&#x02013;48</sub>, AUC<sub>0&#x02013;<italic>t</italic></sub> and <italic>C</italic><sub>max</sub> for total calcitriol were analysed using the same model as for exogenous calcitriol with the exceptions that the log-transformation was applied before analyses and baseline serum calcitriol was not included in the model. The <italic>t</italic><sub>max</sub> values for exogenous and total calcitriol were analysed using Wilcoxon signed-rank sum test.</p></sec></sec><sec sec-type="results" id="sec7"><title>Results</title><p>Volunteer disposition and demographics are shown in <xref rid="tab1 tab2" ref-type="table">Tables&#x000a0;1 and 2</xref>. All 41 participants who were randomized were included in the safety and pharmacokinetic analyses.</p><table-wrap id="tab1" position="float"><label>Table&#x000a0;1</label><caption><p>Volunteer disposition</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr valign="top"><th align="left" rowspan="1" colspan="1">Population</th><th align="left" rowspan="1" colspan="1"><italic>n</italic> (%)</th></tr></thead><tbody><tr valign="top"><td align="left" rowspan="1" colspan="1">Screened</td><td align="left" rowspan="1" colspan="1">86</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Enrolled/randomized</td><td align="left" rowspan="1" colspan="1">41</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Safety population</td><td align="left" rowspan="1" colspan="1">41 (100.0%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Pharmacokinetic population</td><td align="left" rowspan="1" colspan="1">41 (100.0%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">36 (87.8%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Discontinued</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Adverse event</td><td align="left" rowspan="1" colspan="1">0 (0.0%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Refused further participation</td><td align="left" rowspan="1" colspan="1">2 (4.9%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Withdrew consent</td><td align="left" rowspan="1" colspan="1">3 (7.3%)</td></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table&#x000a0;2</label><caption><p>Volunteer demographics (safety population)</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr valign="top"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Total (<italic>n</italic>= 41)</th></tr></thead><tbody><tr valign="top"><td align="left" rowspan="1" colspan="1">Sex, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" rowspan="1" colspan="1">22 (53.7%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" rowspan="1" colspan="1">19 (46.3%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Race, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;White</td><td align="left" rowspan="1" colspan="1">21 (51.2%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Black</td><td align="left" rowspan="1" colspan="1">18 (43.9%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Asian</td><td align="left" rowspan="1" colspan="1">2 (4.9%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Ethnicity, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Hispanic or Latino</td><td align="left" rowspan="1" colspan="1">8 (19.5%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Not Hispanic or Latino</td><td align="left" rowspan="1" colspan="1">33 (80.5%)</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Age, years (mean &#x000b1; SD)</td><td align="left" rowspan="1" colspan="1">30 &#x000b1; 7.6</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Weight, kg (mean &#x000b1; SD)</td><td align="left" rowspan="1" colspan="1">72 &#x000b1; 11.0</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup> (mean &#x000b1; SD)</td><td align="left" rowspan="1" colspan="1">24 &#x000b1; 2.8</td></tr></tbody></table></table-wrap><p>Mean serum concentrations of exogenous and total calcitriol after a single dose, with or without co-administration of lanthanum carbonate or sevelamer carbonate, are shown in <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>. For all regimens, mean exogenous calcitriol concentrations rapidly reached a plateau that was maintained for up to ~&#x02009;6&#x000a0;h, with concentrations then decreasing to a calculated level lower than baseline by 48&#x000a0;h after dosing.</p><fig id="fig2" position="float"><label>Fig.&#x000a0;2</label><caption><p>Mean serum concentrations of (<bold>a</bold>) exogenous and (<bold>b</bold>) total calcitriol after a single dose, with or without co-administration of lanthanum carbonate or sevelamer carbonate. Regimen A: calcitriol 1.0&#x000a0;&#x003bc;g; regimen B: calcitriol 1.0&#x000a0;&#x003bc;g + lanthanum carbonate (1000&#x000a0;mg t.i.d.); regimen C: calcitriol 1.0&#x000a0;&#x003bc;g + sevelamer carbonate (2400&#x000a0;mg t.i.d.).</p></caption><graphic xlink:href="gfq598fig2"/></fig><p>There were no significant changes in exogenous calcitriol least-squares (LS) mean AUC<sub>0&#x02013;48</sub> or <italic>C</italic><sub>max</sub> values when lanthanum carbonate was co-administered with calcitriol, compared with calcitriol alone (<xref rid="tab3" ref-type="table">Table&#x000a0;3</xref>). This was also the case for total calcitriol. However, median <italic>t</italic><sub>max</sub> for exogenous calcitriol and for total calcitriol was longer when lanthanum carbonate was co-administered with calcitriol (calcitriol with lanthanum carbonate: 4.0&#x000a0;h; calcitriol alone: 2.0 h; P = 0.039 for both exogenous calcitriol and total calcitriol) (<xref rid="tab3" ref-type="table">Table&#x000a0;3</xref>).</p><table-wrap id="tab3" position="float"><label>Table&#x000a0;3</label><caption><p>Analysis of exogenous and total calcitriol pharmacokinetic parameters: lanthanum carbonate plus calcitriol versus calcitriol alone</p></caption><table frame="hsides" rules="groups"><tbody><tr valign="top"><td colspan="5" align="left" rowspan="1"><bold>Exogenous calcitriol</bold><xref rid="tfn1" ref-type="table-fn"><sup><bold>a</bold></sup></xref></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>Parameter</italic></td><td align="left" rowspan="1" colspan="1"><italic>Calcitriol</italic></td><td align="left" rowspan="1" colspan="1"><italic>Calcitriol + lanthanum carbonate</italic></td><td align="left" rowspan="1" colspan="1"><italic>Difference (95% CI)</italic></td><td align="left" rowspan="1" colspan="1"><italic>P-value</italic></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">AUC<sub>0&#x02013;48</sub> (pg h/mL)</td><td align="left" rowspan="1" colspan="1">318</td><td align="left" rowspan="1" colspan="1">429</td><td align="left" rowspan="1" colspan="1">111 (&#x02212;&#x02009;49, 270)</td><td align="left" rowspan="1" colspan="1">0.171</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>C</italic><sub>max</sub> (pg/mL)</td><td align="left" rowspan="1" colspan="1">49.7</td><td align="left" rowspan="1" colspan="1">47.0</td><td align="left" rowspan="1" colspan="1">&#x02212;&#x02009;2.7 (&#x02212;&#x02009;8.1, 2.6)</td><td align="left" rowspan="1" colspan="1">0.313</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>t</italic><sub>max</sub> (h)</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">1.3 (0.0, 2.5)</td><td align="left" rowspan="1" colspan="1">0.039</td></tr><tr valign="top"><td colspan="5" align="left" rowspan="1"><bold>Total calcitriol</bold><xref rid="tfn2" ref-type="table-fn"><sup><bold>b</bold></sup></xref></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>Parameter</italic></td><td align="left" rowspan="1" colspan="1"><italic>Calcitriol</italic></td><td align="left" rowspan="1" colspan="1"><italic>Calcitriol + lanthanum carbonate</italic></td><td align="left" rowspan="1" colspan="1"><italic>Geometric mean ratio (95% CI)</italic></td><td align="left" rowspan="1" colspan="1"><italic>P-</italic><italic>value</italic></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">AUC<sub>0&#x02013;48</sub> (pg h/mL)</td><td align="left" rowspan="1" colspan="1">2748</td><td align="left" rowspan="1" colspan="1">2889</td><td align="left" rowspan="1" colspan="1">1.05 (0.99, 1.12)</td><td align="left" rowspan="1" colspan="1">0.114</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>C</italic><sub>max</sub> (pg/mL)</td><td align="left" rowspan="1" colspan="1">98.6</td><td align="left" rowspan="1" colspan="1">96.7</td><td align="left" rowspan="1" colspan="1">0.98 (0.91, 1.05)</td><td align="left" rowspan="1" colspan="1">0.579</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>t</italic><sub>max</sub> (h)</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">1.3 (0.0, 2.5)</td><td align="left" rowspan="1" colspan="1">0.039</td></tr></tbody></table><table-wrap-foot><p>Note: AUC<sub>0&#x02013;<italic>t</italic></sub> values were identical to AUC<sub>0&#x02013;48</sub> values. </p><p>AUC<sub>0&#x02013;48</sub> = area under the serum concentration&#x02013;time curve from time 0 to 48&#x000a0;h after dosing; AUC<sub>0&#x02013;<italic>t</italic></sub> = area under the serum concentration&#x02013;time curve from time 0 to time (<italic>t</italic>) of the last quantifiable plasma concentration; <italic>C</italic><sub>max</sub>, maximum serum concentration; <italic>t</italic><sub>max</sub>, time of maximum serum concentration.</p><fn id="tfn1"><label>a</label><p>Values for AUC and <italic>C</italic><sub>max</sub> are least-squares mean; median values are given for <italic>t</italic><sub>max</sub>.</p></fn><fn id="tfn2"><label>b</label><p>Values for AUC and <italic>C</italic><sub>max</sub> are geometric least-squares mean; median values and median difference are given for <italic>t</italic><sub>max</sub>.</p></fn></table-wrap-foot></table-wrap><p>Co-administration of sevelamer carbonate with calcitriol resulted in a statistically significant reduction in LS mean AUC<sub>0&#x02013;48</sub> for serum exogenous calcitriol levels compared with calcitriol alone {calcitriol with sevelamer carbonate: 137&#x000a0;pg h/mL; calcitriol alone: 318&#x000a0;pg h/mL; difference [95% confidence interval (95% CI)]: &#x02212;&#x02009;181&#x000a0;pg h/mL (&#x02212;&#x02009;338, &#x02212;&#x02009;24.0); P = 0.024} <xref rid="tab4" ref-type="table">(Table&#x000a0;4</xref>). Similarly, co-administration with sevelamer carbonate was associated with a reduction in LS mean <italic>C</italic><sub>max</sub> for exogenous calcitriol levels (calcitriol with sevelamer carbonate: 40.1&#x000a0;pg/mL; calcitriol: 49.7&#x000a0;pg/mL; difference [95% CI]: &#x02212;&#x02009;9.6 [14.9, &#x02212;&#x02009;4.34]; P &#x0003c; 0.001) (<xref rid="tab4" ref-type="table">Table&#x000a0;4</xref>). Significant reductions in LS mean AUC<sub>0&#x02013;48</sub> and <italic>C</italic><sub>max</sub> were also observed for total calcitriol when administered with sevelamer carbonate compared with calcitriol alone (<xref rid="tab4" ref-type="table">Table&#x000a0;4</xref>).</p><table-wrap id="tab4" position="float"><label>Table&#x000a0;4</label><caption><p>Analysis of exogenous calcitriol pharmacokinetic parameters: sevelamer carbonate plus calcitriol versus calcitriol alone</p></caption><table frame="hsides" rules="groups"><tbody><tr valign="top"><td colspan="5" align="left" rowspan="1"><bold>Exogenous calcitriol</bold><xref rid="tfn3" ref-type="table-fn"><sup><bold>a</bold></sup></xref></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>Parameter</italic></td><td align="left" rowspan="1" colspan="1"><italic>Calcitriol</italic></td><td align="left" rowspan="1" colspan="1"><italic>Calcitriol + sevelamer carbonate</italic></td><td align="left" rowspan="1" colspan="1"><italic>Difference (95% CI)</italic></td><td align="left" rowspan="1" colspan="1"><italic>P-value</italic></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">AUC<sub>0&#x02013;48</sub> (pg h/mL)</td><td align="left" rowspan="1" colspan="1">318</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">&#x02212;&#x02009;181 (&#x02212;&#x02009;338, &#x02212;&#x02009;24)</td><td align="left" rowspan="1" colspan="1">0.024</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>C</italic><sub>max</sub> (pg/mL)</td><td align="left" rowspan="1" colspan="1">49.7</td><td align="left" rowspan="1" colspan="1">40.1</td><td align="left" rowspan="1" colspan="1">&#x02212;&#x02009;9.6 (&#x02212;&#x02009;14.9, &#x02212;&#x02009;4.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>t</italic><sub>max</sub> (h)</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">0.5 (&#x02212;&#x02009;0.5, 1.5)</td><td align="left" rowspan="1" colspan="1">0.305</td></tr><tr valign="top"><td colspan="5" align="left" rowspan="1"><bold>Total calcitriol</bold><xref rid="tfn4" ref-type="table-fn"><sup><bold>b</bold></sup></xref></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>Parameter</italic></td><td align="left" rowspan="1" colspan="1"><italic>Calcitriol</italic></td><td align="left" rowspan="1" colspan="1"><italic>Calcitriol + sevelamer carbonate</italic></td><td align="left" rowspan="1" colspan="1"><italic>Geometric mean ratio (95% CI)</italic></td><td align="left" rowspan="1" colspan="1"><italic>P-</italic><italic>value</italic></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">AUC<sub>0&#x02013;48</sub> (pg h/mL)</td><td align="left" rowspan="1" colspan="1">2748</td><td align="left" rowspan="1" colspan="1">2579</td><td align="left" rowspan="1" colspan="1">0.94 (0.88, 1.00)</td><td align="left" rowspan="1" colspan="1">0.047</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>C</italic><sub>max</sub> (pg/mL)</td><td align="left" rowspan="1" colspan="1">98.6</td><td align="left" rowspan="1" colspan="1">89.7</td><td align="left" rowspan="1" colspan="1">0.91 (0.85, 0.98)</td><td align="left" rowspan="1" colspan="1">0.009</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1"><italic>t</italic><sub>max</sub> (h)</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">0.5 (&#x02212;&#x02009;0.5, 1.5)</td><td align="left" rowspan="1" colspan="1">0.305</td></tr></tbody></table><table-wrap-foot><fn><p>Note: AUC<sub>0&#x02013;<italic>t</italic></sub> values were identical to AUC<sub>0&#x02013;48</sub> values.</p><p>AUC<sub>0&#x02013;48</sub> = area under the serum concentration&#x02013;time curve from time 0 to 48&#x000a0;h after dosing; AUC<sub>0&#x02013;<italic>t</italic></sub> = area under the serum concentration&#x02013;time curve from time 0 to time (<italic>t</italic>) of the last quantifiable plasma concentration; <italic>C</italic><sub>max</sub>, maximum serum concentration; <italic>t</italic><sub>max</sub>, time of maximum serum concentration.</p></fn><fn id="tfn3"><label>a</label><p>Values for AUC and <italic>C</italic><sub>max</sub> are least-squares mean; median values are given for <italic>t</italic><sub>max</sub>.</p></fn><fn id="tfn4"><label>b</label><p>Values for AUC and <italic>C</italic><sub>max</sub> are geometric least-squares mean; median values and median difference are given for <italic>t</italic><sub>max</sub>.</p></fn></table-wrap-foot></table-wrap><p>No serious adverse events were reported and none of the volunteers withdrew due to an adverse event. In total, 6/38 individuals (15.8%) experienced adverse events during treatment with calcitriol alone (headache, haematoma, hypoaesthesia [two patients], diarrhoea and urinary tract infection). This compares with 10/38 individuals (26.3%) during treatment with calcitriol and lanthanum carbonate and 5/40 individuals (12.5%) during treatment with calcitriol and sevelamer carbonate. The majority of adverse events were mild or moderate in nature and were not related to lanthanum carbonate or sevelamer carbonate; only three events were considered related to treatment, two occurring during treatment with lanthanum carbonate plus calcitriol (anxiety and headache) and one occurring during treatment with sevelamer carbonate and calcitriol (dry mouth). No clinically important changes in laboratory parameters, physical examinations or electrocardiograms were detected during the study in any of the treatment arms.</p></sec><sec sec-type="discussion" id="sec8"><title>Discussion</title><p>The results of this study demonstrate that, unlike lanthanum carbonate, sevelamer carbonate reduces serum levels of exogenous calcitriol when these agents are co-administered.</p><p>Our study showed that sevelamer carbonate reduced the systemic exposure to oral calcitriol (measured as AUC<sub>0&#x02013;48</sub>) by ~&#x02009;57%, whereas lanthanum carbonate had no statistically significant or clinically relevant effect. Furthermore, <italic>C</italic><sub>max</sub> for calcitriol was significantly (19%) lower when volunteers were co-administered with sevelamer carbonate and calcitriol compared with calcitriol alone. Our results extend to human details contained within the prescribing information for sevelamer carbonate, which highlight reductions in vitamin D levels in rats and dogs when given sevelamer hydrochloride and suggest monitoring for reduced vitamin D [<xref rid="ref28" ref-type="bibr">28</xref>]. In contrast to the results with sevelamer carbonate, lanthanum carbonate had no significant effect on <italic>C</italic><sub>max</sub>. These findings are in line with previous observations by Finn <italic>et al.</italic> who showed that lanthanum carbonate does not affect concentrations of 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D (the inactive and active forms of vitamin D, respectively) in patients with CKD stages 3 and 4 [<xref rid="ref29" ref-type="bibr">29</xref>].</p><p>A direct impact of sevelamer on calcitriol metabolism is unlikely because absorption of sevelamer is negligible [<xref rid="ref30" ref-type="bibr">30</xref>]. However, an indirect interaction (by altering the absorption of an agent that affected calcitriol metabolism) cannot be entirely excluded. A more likely explanation for the reduction in AUC<sub>0&#x02013;48</sub> is that the non-selective binding properties of sevelamer result in reduced absorption of both phosphate and calcitriol. Sevelamer consists of a cross-linked polyallyl skeleton with protonated primary and secondary amine groups [<xref rid="ref31" ref-type="bibr">31</xref>]. The hydrocarbon polymer will have affinity for aliphatic polycyclic molecules (e.g. bile acids, vitamin D, vitamin K) through intermolecular van der Waals attraction [<xref rid="ref31" ref-type="bibr">31</xref>]. Indeed, sevelamer has been proven to bind the fat-soluble vitamin K <italic>in vitro</italic>, fully sequestering a test sample [<xref rid="ref32" ref-type="bibr">32</xref>].</p><p>Co-administration of calcitriol with lanthanum carbonate resulted in a delay in <italic>t</italic><sub>max</sub> compared with calcitriol alone. However, examination of all the concentration&#x02013;time curves suggests that a plateau is rapidly reached and maintained for at least 5&#x000a0;h. For the calcitriol alone regimen, the concentration at 2&#x000a0;h was transiently higher but declined to a plateau consistent with levels seen with the calcitriol/lanthanum carbonate regimen by the time of the next sampling point. Given this observation, it is possible that the apparent difference in <italic>t</italic><sub>max</sub> (2&#x000a0;h for calcitriol only; 4&#x000a0;h for calcitriol with lanthanum carbonate) is a chance finding. Even if there is some reduction in the absorption rate of calcitriol when given with lanthanum carbonate, it is unlikely to have any clinical impact because systemic exposure is not significantly altered. Results for total calcitriol were consistent with those for exogenous calcitriol.</p><p>In this study, volunteers received a single dose of calcitriol alone (1&#x000a0;&#x003bc;g at lunch), a single dose of calcitriol plus three doses of lanthanum carbonate (1000&#x000a0;mg at breakfast, lunch and dinner) or a single dose of calcitriol plus three doses of sevelamer carbonate (2400&#x000a0;mg at breakfast, lunch and dinner). We acknowledge that the co-administration of oral calcitriol and phosphate-binding agents in this regimen may not be representative of how these treatments are taken by patients in clinical practice. There are no specific guidelines regarding when oral calcitriol should be taken relative to phosphate binders but, for convenience, patients receiving oral vitamin D supplements and phosphate binders may take the agents simultaneously in the absence of guidance concerning any drug&#x02013;drug interaction.</p><p>An interesting observation in this study is the apparent fall of serum calcitriol concentrations below baseline levels for all treatment regimens by 48&#x000a0;h post-dose. The reason for this phenomenon is unclear. There are data to suggest that calcitriol administration can induce production of 24-hydroxylase [<xref rid="ref33" ref-type="bibr">33</xref>], thus degrading calcitriol and maintaining calcium balance. In theory, this induction could lead to a reduction in overall calcitriol levels compared with baseline. However, in a previous pharmacokinetic study of calcitriol in healthy individuals, calcitriol concentrations did not return to baseline within a 24-h period [<xref rid="ref34" ref-type="bibr">34</xref>]. Therefore, the results in our study cannot be unequivocally attributed to induction of 24-hydroxylase. On examining the concentration&#x02013;time curves, it is clear that the standard deviations about the mean calcitriol concentrations for baseline and 48-h values overlap. Hence, there is some uncertainty whether the apparent decline in calcitriol concentrations below baseline is real.</p></sec><sec><title>Conclusion</title><p>Sevelamer carbonate significantly reduces serum concentrations of exogenous calcitriol when co-administered with oral calcitriol in healthy volunteers, whereas lanthanum carbonate has no clinically relevant effect on exogenous calcitriol. The most likely explanation for the effect of sevelamer is a reduction in bioavailability through sequestering the fat-soluble calcitriol. These findings may represent an important consideration in patients with CKD who often require vitamin D supplementation.</p></sec></body><back><ack><p>The authors would like to thank Pinggao Zhang from Shire Pharmaceuticals and Apinya Bee Vutikullird from West Coast Clinical Trials for their contribution to this study. Our gratitude also goes to Phil Wang (Shire Pharmaceuticals) and AAI Pharma for bioanalysis. This study was funded by Shire Pharmaceuticals. Oxford PharmaGenesis&#x02122; provided editorial support to the authors.</p><p><italic>Conflict of interest statement.</italic> All authors, except SH, are employees of Shire Pharmaceuticals. SH received funding for this study. The results have not been published in whole or in part elsewhere with the exception of congress abstracts.</p></ack><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaClair</surname><given-names>RE</given-names></name><name><surname>Hellman</surname><given-names>RN</given-names></name><name><surname>Karp</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States</article-title><source>Am J Kidney Dis</source><year>2005</year><volume>45</volume><fpage>1026</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">15957131</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Pesenson</surname><given-names>A</given-names></name><name><surname>Maski</surname><given-names>M</given-names></name><name><surname>Kaufman</surname><given-names>J</given-names></name></person-group><article-title>Prevalence of 25-OH vitamin D deficiency in patients with chronic kidney disease and effects of correction following KDOQI guidelines</article-title><year>2006</year><conf-name>Poster Presentation at the American Society of Nephrology Renal Week</conf-name><conf-loc>San Diego, CA, USA</conf-loc><fpage>14</fpage><lpage>19</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craver</surname><given-names>L</given-names></name><name><surname>Marco</surname><given-names>MP</given-names></name><name><surname>Martinez</surname><given-names>I</given-names></name><etal/></person-group><article-title>Mineral metabolism parameters throughout chronic kidney disease stages 1&#x02013;5&#x02014;achievement of K/DOQI target ranges</article-title><source>Nephrol Dial Transplant</source><year>2007</year><volume>22</volume><fpage>1171</fpage><lpage>1176</lpage><pub-id pub-id-type="pmid">17205962</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Badr</surname><given-names>W</given-names></name><name><surname>Martin</surname><given-names>KJ</given-names></name></person-group><article-title>Vitamin D and kidney disease</article-title><source>Clin J Am Soc Nephrol</source><year>2008</year><volume>3</volume><fpage>1555</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">18450926</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>TJ</given-names></name><name><surname>Pencina</surname><given-names>MJ</given-names></name><name><surname>Booth</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Vitamin D deficiency and risk of cardiovascular disease</article-title><source>Circulation</source><year>2008</year><volume>117</volume><fpage>503</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">18180395</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulie</surname><given-names>T</given-names></name><name><surname>Groff</surname><given-names>A</given-names></name><name><surname>Redmer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Vitamin D: an evidence-based review</article-title><source>J Am Board Fam Med</source><year>2009</year><volume>22</volume><fpage>698</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">19897699</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eknoyan</surname><given-names>G</given-names></name><name><surname>Levin</surname><given-names>A</given-names></name><name><surname>Levin</surname><given-names>NW</given-names></name></person-group><article-title>Bone metabolism and disease in chronic kidney disease</article-title><source>Am J Kidney Dis</source><year>2003</year><volume>42</volume><fpage>1</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">12500213</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Kidney Disease: Improving Global Outcomes (KDIGO) CKD&#x02013;MBD Work Group</collab></person-group><article-title>KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease&#x02013;mineral and bone disorder (CKD&#x02013;MBD)</article-title><source>Kidney Int</source><year>2009</year><volume>76</volume><fpage>S1</fpage><lpage>S130</lpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritz</surname><given-names>E</given-names></name><name><surname>Kuster</surname><given-names>S</given-names></name><name><surname>Schmidt-Gayk</surname><given-names>H</given-names></name><etal/></person-group><article-title>Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)</article-title><source>Nephrol Dial Transplant</source><year>1995</year><volume>10</volume><fpage>2228</fpage><lpage>2234</lpage><pub-id pub-id-type="pmid">8808216</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Gutierrez</surname><given-names>O</given-names></name><etal/></person-group><article-title>Vitamin D levels and early mortality among incident hemodialysis patients</article-title><source>Kidney Int</source><year>2007</year><volume>72</volume><fpage>1004</fpage><lpage>1013</lpage><pub-id pub-id-type="pmid">17687259</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleyer</surname><given-names>AJ</given-names></name><name><surname>Burke</surname><given-names>SK</given-names></name><name><surname>Dillon</surname><given-names>M</given-names></name><etal/></person-group><article-title>A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>1999</year><volume>33</volume><fpage>694</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">10196011</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchison</surname><given-names>AJ</given-names></name><name><surname>Maes</surname><given-names>B</given-names></name><name><surname>Vanwalleghem</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate</article-title><source>Nephron Clin Pract</source><year>2005</year><volume>100</volume><fpage>c8</fpage><lpage>c19</lpage><pub-id pub-id-type="pmid">15809508</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suki</surname><given-names>WN</given-names></name><name><surname>Zabaneh</surname><given-names>R</given-names></name><name><surname>Cangiano</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients</article-title><source>Kidney Int</source><year>2007</year><volume>72</volume><fpage>1130</fpage><lpage>1137</lpage><pub-id pub-id-type="pmid">17728707</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Smyth</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy</article-title><source>Curr Med Res Opin</source><year>2009</year><volume>25</volume><fpage>3021</fpage><lpage>3028</lpage><pub-id pub-id-type="pmid">19845495</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>GA</given-names></name><name><surname>Spiegel</surname><given-names>DM</given-names></name><name><surname>Ehrlich</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis</article-title><source>Kidney Int</source><year>2005</year><volume>68</volume><fpage>1815</fpage><lpage>1824</lpage><pub-id pub-id-type="pmid">16164659</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braunlin</surname><given-names>W</given-names></name><name><surname>Zhorov</surname><given-names>E</given-names></name><name><surname>Guo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Bile acid binding to sevelamer HCl</article-title><source>Kidney Int</source><year>2002</year><volume>62</volume><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">12110025</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Autissier</surname><given-names>V</given-names></name><name><surname>Damment</surname><given-names>SJ</given-names></name><name><surname>Henderson</surname><given-names>RA</given-names></name></person-group><article-title>Relative <italic>in vitro</italic> efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride</article-title><source>J Pharm Sci</source><year>2007</year><volume>96</volume><fpage>2818</fpage><lpage>2827</lpage><pub-id pub-id-type="pmid">17497733</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>DR</given-names></name></person-group><article-title>Vitamin D</article-title><source>Lancet</source><year>1995</year><volume>345</volume><fpage>104</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">7815853</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="book"><source>US Prescribing Information Renagel (Sevelamer hydrochloride)</source><date-in-citation>(20 September 2010, date last accessed)</date-in-citation><publisher-loc>Silver Spring, MD, USA</publisher-loc><publisher-name>Center for Drug Evaluation and Research</publisher-name><comment>http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021179s020lbl.pdf</comment></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchison</surname><given-names>AJ</given-names></name><name><surname>Barnett</surname><given-names>ME</given-names></name><name><surname>Krause</surname><given-names>R</given-names></name><etal/></person-group><article-title>Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment</article-title><source>Nephron Clin Pract</source><year>2008</year><volume>110</volume><fpage>c15</fpage><lpage>c23</lpage><pub-id pub-id-type="pmid">18667837</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>WF</given-names></name></person-group><article-title>Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients</article-title><source>Clin Nephrol</source><year>2006</year><volume>65</volume><fpage>191</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">16550750</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ketteler</surname><given-names>M</given-names></name><name><surname>Rix</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis</article-title><source>Clin J Am Soc Nephrol</source><year>2008</year><volume>3</volume><fpage>1125</fpage><lpage>1130</lpage><pub-id pub-id-type="pmid">18450923</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evenepoel</surname><given-names>P</given-names></name><name><surname>Selgas</surname><given-names>R</given-names></name><name><surname>Caputo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><fpage>278</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">18820280</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>C</given-names></name><name><surname>Mitra</surname><given-names>S</given-names></name><etal/></person-group><article-title>A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><fpage>3794</fpage><lpage>3799</lpage><pub-id pub-id-type="pmid">19666658</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slatopolsky</surname><given-names>EA</given-names></name><name><surname>Burke</surname><given-names>SK</given-names></name><name><surname>Dillon</surname><given-names>MA</given-names></name></person-group><article-title>RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group</article-title><source>Kidney Int</source><year>1999</year><volume>55</volume><fpage>299</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">9893140</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Burke</surname><given-names>SK</given-names></name><name><surname>Raggi</surname><given-names>P</given-names></name></person-group><article-title>Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients</article-title><source>Kidney Int</source><year>2002</year><volume>62</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">12081584</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="other"><comment>Application Number 021068 and 18044/S025. <italic>Clinical Pharmacology and Biopharmaceutics Review(S)</italic>. Silver Spring, MD, USA: Center for Drug Evaluation and Research. http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/021068a_clinphrm.pdf (11 February 2010, date last accessed)</comment></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="other"><comment>Genzyme Therapeutics. <italic>Renvela Prescribing Information</italic>. 2008. http://www.renvela.com/docs/renvela_PI.pdf (11 February 2010, date last accessed)</comment></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>W</given-names></name><name><surname>Sprague</surname><given-names>S</given-names></name><name><surname>Abboud</surname><given-names>H</given-names></name><etal/></person-group><article-title>25-Hydroxyvitamin D levels in patients with CKD Stage 3 and 4 are not affected by lanthanum carbonate: results from a randomized multicentre trial</article-title><source>Nephrol Dial Transplant</source><year>2008</year><volume>1</volume><fpage>ii59</fpage></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plone</surname><given-names>MA</given-names></name><name><surname>Petersen</surname><given-names>JS</given-names></name><name><surname>Rosenbaum</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Sevelamer, a phosphate-binding polymer, is a non-absorbed compound</article-title><source>Clin Pharmacokinet</source><year>2002</year><volume>41</volume><fpage>517</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">12083979</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrong</surname><given-names>O</given-names></name><name><surname>Harland</surname><given-names>C</given-names></name></person-group><article-title>Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure</article-title><source>Nephron Physiol</source><year>2007</year><volume>107</volume><fpage>17</fpage><lpage>33</lpage></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takagi</surname><given-names>K</given-names></name><name><surname>Masuda</surname><given-names>K</given-names></name><name><surname>Yamazaki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins</article-title><source>Clin Nephrol</source><year>2010</year><volume>73</volume><fpage>30</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">20040349</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemay</surname><given-names>J</given-names></name><name><surname>Demers</surname><given-names>C</given-names></name><name><surname>Hendy</surname><given-names>GN</given-names></name><etal/></person-group><article-title>Expression of the 1,25-dihydroxyvitamin D3-24-hydroxylase gene in rat intestine: response to calcium, vitamin D3 and calcitriol administration <italic>in vivo</italic></article-title><source>J Bone Miner Res</source><year>1995</year><volume>10</volume><fpage>1148</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">8585417</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>SE</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>CK</given-names></name></person-group><article-title>Pharmacokinetics of oral calcitriol in healthy human based on the analysis with an enzyme immunoassay</article-title><source>Pharmacol Res</source><year>2009</year><volume>60</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">19427587</pub-id></element-citation></ref></ref-list></back></article>